RT Journal Article SR Electronic T1 Prognostic peripheral blood biomarkers at ICU admission predict COVID-19 clinical outcomes JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2022.01.31.22270208 DO 10.1101/2022.01.31.22270208 A1 Melina Messing A1 Mypinder S. Sekhon A1 Michael R. Hughes A1 Sophie Stukas A1 Ryan L. Hoiland A1 Jennifer Cooper A1 Nyra Ahmed A1 Mark Hamer A1 Yicong Li A1 Samuel B. Shin A1 Lin Wei Tung A1 Cheryl Wellington A1 Don D. Sin A1 Kevin B. Leslie A1 Kelly M. McNagny YR 2022 UL http://medrxiv.org/content/early/2022/02/01/2022.01.31.22270208.abstract AB The COVID-19 pandemic continues to challenge the capacities of hospital ICUs which currently lack the ability to identify prospectively those patients who may require extended management. In this study of 90 ICU COVID-19 patients, we used multiplexed cytokine evaluation and, on 42 of these patients (binned into Initial and Replication Cohorts), CyTOF-based deep immunophenotyping. This revealed blood prognostic biomarkers that, at time of ICU admission, prospectively distinguish, with 91% sensitivity and 91% specificity, patients who will subsequently die or have long ICU stays (≥ 6 days) from those who will have short-stays (< 6 days). This is achieved through a tiered evaluation of serum IL-10 and targeted immunophenotyping of monocyte subsets (specifically, CD11clow classical monocytes) through statistical approaches. We have distilled this down to a prognostic test that could prove useful in guiding clinical resource allocation, treatment regimens and assessment of new therapeutic interventions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by St. Paul's Foundation and the Thistledown FoundationAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The University of British Columbia Clinical Research Ethics board gave ethics approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.